Semaglutide for Smoking Cessation in Patients With Diabetes
Recruiting
Phase 3
Interventional Study
Diabetes Mellitus, Type 2
Nicotine Addiction
Tobacco Dependence
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 100 (estimated)
- Sponsor
- Ottawa Heart Institute Research Corporation · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
To assess the feasibility of conducting a randomized controlled trial (RCT) to determine the effectiveness of semaglutide as an adjunct to combination NRT in supporting smoking cessation for patients with diabetes.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adults (18 years or older) with type 2 diabetes
* Currently residing in Ontario
* Smoke at least five cigarettes per day and willing to reduce or quit smoking within the next 6 months
* Stable HbA1c ≥7.0% - 10% with no more than a 1% change over the last 3 to 6 months.
* Have …
Contacts